Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Parallel-group, Phase IIb, Randomised, Double-blind, Placebo-controlled, 3-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO)

NCT07082738 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07082738
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07082738 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Parallel-group, Phase IIb, Randomised, Double-blind, Placebo-controlled, 3-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO)
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Recruiting
Start date
June 27, 2025
Completion date
November 5, 2027
Enrollment
987 (estimated)
Sites
367

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease (copd)